Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.05% is 94% below its 5-year average of 0.84%, near the low end of its 5-year range (0.00%–18.65%).
As of the fiscal period ended Tuesday, June 30, 2026. 82.83% below its 12-month average of 0.30%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05%.
DEBT TO ASSETS RATIO
0.05%
DEBT TO ASSETS RATIO AVG TTM
0.30%
DEBT TO ASSETS RATIO AVG 3Y
0.45%
DEBT TO ASSETS RATIO AVG 5Y
0.84%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-82.83%
CURRENT VS 3Y AVG
-88.55%
CURRENT VS 5Y AVG
-93.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 597 covered companies
CURRENT VS SECTOR MEDIAN
-48.44%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$116.64M
Debt to Assets Ratio
0.05%
TTM Avg
0.30%
3Y Avg
0.45%
5Y Avg
0.84%
Market Cap
$116.57M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.50M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.79M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$120.24M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.52M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$121.25M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.89M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $116.64M | 0.05% | 0.30% | 0.45% | 0.84% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 0.09% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.50M | 0.19% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.79M | 0.09% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 0.09% | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | 0.01% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | 0.64% | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 0.12% | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $111.89M | 0.00% | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | 0.04% | N/A | N/A | N/A |
Debt/Assets
0.1%
Debt/Equity
0.00
Current Ratio
13.55
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.05% |
| 2026-03-31 | 0.25% |
| 2025-12-31 | 0.27% |
| 2025-09-30 | 0.45% |
| 2025-06-30 | 0.48% |
| 2025-03-31 | 0.59% |
| 2024-12-31 | 0.64% |
| 2024-09-30 | 0.70% |
| 2024-06-30 | 0.84% |
| 2024-03-31 | 0.27% |
| 2023-12-31 | 0.47% |
| 2023-09-30 | 0.39% |
| 2023-06-30 | 18.65% |
| 2023-03-31 | 1.46% |
| 2022-12-31 | 0.53% |
| 2022-09-30 | 2.09% |
| 2022-06-30 | 2.31% |
| 2022-03-31 | 2.69% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 2.28% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
